OBJECTIVE: To evaluate the outcomes and timing of intervention for adrenal-sparing surgery in patients left with a solitary adrenal remnant after bilateral adrenal surgeries. PATIENTS AND METHODS: Patients were included in the study if they had undergone bilateral adrenal surgery as a treatment for phaeochromocytoma and were left with a solitary adrenal remnant. Perioperative, functional and oncological outcomes were evaluated in 21 patients who met the inclusion criteria. RESULTS: There was minimal perioperative morbidity and no perioperative mortality. After a median (range) follow-up of 21 (3-143) months, there were two cases of persistent disease. Ten patients (48%) required steroid supplementation upon discharge, with four subsequently discontinuing this treatment. Patients were more likely to require steroid supplementation after surgery if they underwent simultaneous adrenalectomy and contralateral partial adrenalectomy, rather than staged procedures (86 vs 40%, P = 0.02). Patients who underwent surgery for tumours > 4 cm were more likely to require long-term steroids than patients who underwent surgery for lesions < 4 cm (75 vs 18%, P = 0.05). CONCLUSIONS: Patients left with a solitary adrenal remnant after bilateral adrenal surgery have low surgical morbidity, reasonable functional outcomes and low rates of recurrence at an intermediate follow-up period. A staged approach could decrease the immediate postoperative need for steroids, and intervention before the largest tumour reaches 4 cm could decrease the rate of long-term steroid dependence.
OBJECTIVE: To evaluate the outcomes and timing of intervention for adrenal-sparing surgery in patients left with a solitary adrenal remnant after bilateral adrenal surgeries. PATIENTS AND METHODS: Patients were included in the study if they had undergone bilateral adrenal surgery as a treatment for phaeochromocytoma and were left with a solitary adrenal remnant. Perioperative, functional and oncological outcomes were evaluated in 21 patients who met the inclusion criteria. RESULTS: There was minimal perioperative morbidity and no perioperative mortality. After a median (range) follow-up of 21 (3-143) months, there were two cases of persistent disease. Ten patients (48%) required steroid supplementation upon discharge, with four subsequently discontinuing this treatment. Patients were more likely to require steroid supplementation after surgery if they underwent simultaneous adrenalectomy and contralateral partial adrenalectomy, rather than staged procedures (86 vs 40%, P = 0.02). Patients who underwent surgery for tumours > 4 cm were more likely to require long-term steroids than patients who underwent surgery for lesions < 4 cm (75 vs 18%, P = 0.05). CONCLUSIONS:Patients left with a solitary adrenal remnant after bilateral adrenal surgery have low surgical morbidity, reasonable functional outcomes and low rates of recurrence at an intermediate follow-up period. A staged approach could decrease the immediate postoperative need for steroids, and intervention before the largest tumour reaches 4 cm could decrease the rate of long-term steroid dependence.
Authors: Linwah Yip; Jeffrey E Lee; Suzanne E Shapiro; Steven G Waguespack; Steven I Sherman; Ana O Hoff; Robert F Gagel; James F Arens; Douglas B Evans Journal: J Am Coll Surg Date: 2004-04 Impact factor: 6.113
Authors: Gopal N Gupta; Jonas S Benson; Michael J Ross; Vani S Sundaram; Kelly Y Lin; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky Journal: J Endourol Date: 2013-10-23 Impact factor: 2.942
Authors: Maximilian Lerchenberger; Ufuk Gündogar; Norah Al Arabi; Julia K S Gallwas; Herbert Stepp; Klaus K J Hallfeldt; Roland Ladurner Journal: Surg Endosc Date: 2019-07-24 Impact factor: 4.584
Authors: Kevin P Asher; Gopal N Gupta; Ronald S Boris; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky Journal: Eur Urol Date: 2011-04-09 Impact factor: 20.096
Authors: Thomas Sanford; Patrick T Gomella; Rashid Siddiqui; Daniel Su; Julie Y An; Gennady Bratslavsky; Mark W Ball; W Marston Linehan; Adam R Metwalli Journal: Urol Oncol Date: 2020-12-08 Impact factor: 2.954